Dr. Gabi Hanna, M.D. is a drug development expert with a focus on translational research to bring therapeutics to market on accelerated timeframes.
Dr. Hanna joined Duke University Medical Center in 2008 as a senior research associate, and in 2016 was selected to found and lead the Duke Preclinical Translational Research Center. Under Dr. Hanna’s leadership, the Duke PTRC is one of the first academic research units in the world dedicated to advancing translational research through rigorous implementation of a comprehensive drug development program. He has been a member of the Duke University Health System Institutional Medical Review Board (IRB) since 2009.
In 2017, Dr. Hanna co-founded an academic consortium for knowledge and resource-sharing to advance and accelerate drug development, and became a member of the national CTSI cohort, the nation’s largest initiative to advance translational medicine, which currently has 45 member-universities.
Dr. Hanna is the CEO and co-founder of Lamassa Pharma, LLC, a small commercial drug development firm dedicated to bringing novel therapeutics to market more quickly. Lamassu’s first therapeutic, RABI-767—a novel therapeutic for the treatment of severe acute pancreatitis—was licensed from the Mayo Clinic in early 2021, and successfully completed pre-clinical just months later, positioning the company to begin Phase 1 Clinical Trials in Fall 2021. The company received an NIH grant in 2020 to support this vital research. Lamassu Pharma is also researching additional new genetic therapies for rare diseases and the company is expanding partnerships with major universities and private companies to further support innovation and acceleration in drug development.
Dr. Hanna received his M.D. from Aleppo University Medical Center in 2005. He completed his plastic and general surgery internship at the University of Texas in 2006, and held a post-doctoral fellowship in the Department of Surgery Oncology at Duke University from 2006-2008.
Dr. Hanna is the Chairman of the North Carolina Society of Physician Entrepreneurs and a board member and advisor for multiple companies, including Kaio Therapy, Clickmedix, Remote Health, and Zoonco. He is an avid writer, and has contributed content on translational research to multiple publications including Forbes and Drug Discovery & Development.